What is BioLoomics?
BioLoomics is at the forefront of advanced laboratory research, specializing in the development of Super-ADCs (Antibody-Drug Conjugates). The company's innovative programs, including Directed Evolution, are designed to serve clients within the biotechnology and pharmaceutical industries. BioLoomics prioritizes client privacy and a seamless user experience on its digital platform.
How much funding has BioLoomics raised?
BioLoomics has raised a total of $8.7M across 1 funding round:
Angel/Seed
$8.7M
Angel/Seed (2023): $8.7M with participation from Innovation Endeavors, Horizons Ventures, and BoxOne Ventures
Key Investors in BioLoomics
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders and transformational technologies, with a focus on the Super Evolution thesis combining data, computation, and engineering across various industries including life sciences.
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity, supporting innovative projects with the potential for transformative change in science and technology sectors.
BoxOne Ventures
BoxOne Ventures Inc operates within the Credit Cards & Transaction Processing industry, indicating a potential interest in the financial infrastructure supporting emerging technology companies.
What's next for BioLoomics?
With a major enterprise-level funding context and a recent strategic investment, BioLoomics is poised for significant scaling and further development of its Super-ADC technology. This capital infusion is expected to accelerate research initiatives, expand its service offerings to a broader client base in the biotech and pharma sectors, and potentially drive the commercialization of its proprietary Directed Evolution platforms. The company's trajectory suggests a focus on solidifying its market position and advancing its pipeline of innovative therapeutic solutions.
See full BioLoomics company page
